Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questions it aims to answer are: \- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles? Participants will: * Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.

NCT Number	NCT06977594
Lead Sponsor	Seoul National University Hospital Collaborators: Seoul National University Bundang Hospital, Seoul National University Boramae Hospital, Korea Health Industry Development Institute
Conditions	Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Enrollment	1,000 participants
Start Date	2025-06-25
Primary Completion	2027-05-31 (estimated)
Study Completion	2028-05-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-24